The head of Instagram has dismissed claims that the social media platform is “clinically addictive” while testifying in a major court case. During the landmark trial, the executive argued that the app is designed to connect people and encourage creativity, not to create unhealthy dependence among users. The case has drawn global attention as concerns continue to grow over the effects of social media on mental health.

In court, the Instagram chief rejected accusations that the company intentionally designs features to keep users hooked in a harmful way. He explained that while the platform uses tools to improve user experience and engagement, these are common across many digital services. According to him, labeling Instagram as medically addictive is inaccurate and not supported by scientific consensus.

The trial is part of a broader legal battle involving technology companies and questions about their responsibility toward users, especially teenagers. Critics argue that social media platforms contribute to anxiety, depression, and excessive screen time. However, Instagram’s leadership maintains that the company has introduced safety features, parental controls, and time-management tools to support healthier usage.

As the case continues, it is expected to influence future regulations for tech companies and online platforms. The outcome could shape how governments address digital wellbeing and platform accountability. For now, Instagram remains firm in its position that it does not meet the definition of a clinically addictive product.